| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55fa76c9b7175910a5bffb3e26fb5b2a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001129
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b08fa9a9b671863cbdcf173120129d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc9413366554215c39ddd317104e2c28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd838b428623d411fd04217fef3cb3c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b1a1746cad2c6a0b892f99c55b603ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_168bf40a1380e89ddcbc9e5d825b07f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04844f5f9813b25ad68c2ae652d4fd97 |
| publicationDate |
2022-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3953391-A1 |
| titleOfInvention |
Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies |
| abstract |
The present invention is directed to a dosing regimen for administering a CD 123 x CDS bispecific diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The present invention is also directed to a dosing regimen for administering a CD 123 x CDS bispecific diabody in combination with a molecule capable of binding PD-1 or a natural ligand of PD-1 (a "PD-1 or PD-1 ligand binding molecule") to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such regimens for administering the sequence-optimized CD 123 x CDS bispecific diabody, "DART-A," which is capable of simultaneous binding to CD 123 and CDS. |
| priorityDate |
2019-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |